Actinogen Limited (ASX:ACW)
CEO Dr Bill Ketelbey told the conference ‘Alzheimer’s disease is emerging as one of the most significant health challenges of our time. A person develops Alzheimer’s disease almost every minute in the US.’
Dr Ketelbey outlined the development and milestones of the company’s lead drug Xanamem, most recently the completion of a second Phase I trial.
The biotechnology company is now preparing for a Phase II trial. The trial will be a double blind, randomised, placebo controlled study to assess the safety, tolerability and efficacy of Xanamem in participants with mild Alzheimer's disease.